TheraRadar
Data updated: May 26, 2026

MILPROSA (progesterone)

Women's Health Approved 2020-04-29
1
Indication
--
Phase 3 Trials
6
Years on Market

Details

Status
Discontinued
First Approved
2020-04-29
Patent Cliff
2030

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
VAGINAL
Dosage Forms
SYSTEM

Companies

Active Ingredient: PROGESTERONE

MILPROSA Approval History

2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2020 to 2020
Apr 2020 ORIGINAL
New Form · Type 3 - New Dosage Form

What MILPROSA Treats

1 FDA approvals

Originally approved for its first indication in 2020 .

  • Other (1)
📋

Clinical Trial Registry

62 trials
Trial Sponsor ID Phase Status Title
NCT06668896 DARE-PTB1-001 1R44HD101169-01A1 Ph 1 not yet recruiting Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vaginal Insert
NCT06851754 10002141 002141-CH Ph 3 recruiting Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency
NCT07508657 LIFT 05112025 2025-524327-53-00 Ph 4 not yet recruiting Progesterone Supplementation After Letrozole-stimulated Insemination
NCT04675788 2005890134 1R01HL153114-01 Ph 4 completed Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
NCT04499131 PROGENDO 1901-VLC-014-EL Ph 4 completed Impact of Different Doses and Routes of Exogenous Progesterone Administration on Endometrial Receptivity Parameters
NCT06807580 STUDY00006161 2025P011358 Ph 2 recruiting Progesterone in Gender Affirming Hormone Therapy Study
NCT05704036 STURDY IRB00307525 Ph 4 recruiting Estrogen Supplementation and Bone Health in Women With CF
NCT06610305 PEAR 24-1715 1R01MH122446 Ph 4 recruiting Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression
NCT07162961 New IVF Ph 3 not yet recruiting Nintedanib for Improving Reproductive Outcomes in Adenomyosis
NCT03834883 results posted 1806935117 Ph 4 completed Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
NCT06631547 Pgs in head trauma Ph 1 not yet recruiting Effect of Progesterone Administration on Severely Head Injured Patients
NCT03018366 results posted PRO26081 Ph 2 completed Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women
NCT05903820 REBEL NL83336.018.23 Ph 4 completed Rhythmic Estradiol and Bone Health
NCT04209543 MIT-Do001-C301 Ph 3 completed Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)
NCT05286554 0201599 Ph 4 completed Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support
NCT04997525 ESTRO-FET 2020-001218-39 Ph 4 completed Estradiol and Progesterone Levels Following Frozen Embryo Transfer
NCT06091436 ANGAS GenSci094-301 Ph 3 completed To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference
NCT01143064 SyNAPSe results posted BHR-100-301 2010-018283-16 Ph 3 completed Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury
NCT03729869 results posted Pro00081360 2U54DA016511-16 Ph 2 completed Impact of Progesterone on Stress Reactivity and Cannabis Use
NCT04414761 JIAI 2020-06 Ph 3 completed Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response
NCT02133573 results posted 13-010710 Ph 2 completed Randomized Trial of Maternal Progesterone Therapy
NCT03619707 AmericanUBMC-CWET Ph 4 completed Oral Versus Vaginal Progesterone in the Luteal Support in Cryo-warmed Embryo Transfer Cycles
NCT03930212 Prothreat Prog133077 Ph 4 completed Progesterone Supplementation in Threatened Abortion
NCT02187224 results posted 1603017361 24330 Ph 2, Ph 3 completed Progesterone Effect on Individuals Diagnoses With AD and PTSD.
NCT01954966 results posted 811940 K24DA030301 Ph 4 completed Progesterone and Brain Imaging Study
NCT04507022 RFC041120190008 Ph 4 completed The Outcome of Two Protocols Used to Prepare Endometrium for Frozen Embryo Transfer
NCT04537078 results posted 0201350 Ph 3 completed Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders
NCT01599494 P07056 MK-8962-029 Ph 3 withdrawn An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)
NCT03463252 ZHENG Ying Ph 2, Ph 3 recruiting Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
NCT02846909 PCR Ph 2 completed The Vaginal Progesterone and Cerclage
NCT02145767 PRMT15 Ph 2 completed Progesterone for the Prevention of Miscarriage and Preterm Birth in Women With First Trimester Bleeding: PREEMPT Trial
NCT01441635 results posted M12-663 Ph 2 completed Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids
NCT04748562 MS 483/2019 Ph 4 completed Vaginal Progesterone 400mg v.s 200mg for Prevention of Preterm Labor in Twin Pregnancies
NCT03540225 POPPET 2016.594-T Ph 3 withdrawn Vaginal Progesterone for the Prevention of Preterm Birth in Twins
NCT02697331 AIN-2222-RCT Ph 3 completed Vaginal Progesterone in Twin With Short Cervix
NCT02255175 PEERS results posted 13-3572 K12HD001441-15, K23MH105569-01A1 Ph 4 completed Perimenopausal Effects of Estradiol on Reward Responsiveness
NCT02032797 PROFETA-5 PROFETA-5 Ph 4 completed Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved(Frozen)-Thawed Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone.
NCT01940653 PROFETA-3 PROFETA-3 Ph 4 completed Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved (Frozen)-Thawed Day 3 Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone
NCT02513940 results posted 1507526854 Ph 4 completed Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT01942668 REPLENISH results posted TXC12-05 REPLENISH Trial Ph 3 completed A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
NCT01809639 results posted IRB00021983 Ph 4 completed Does Oral Micronized Progesterone Shorten Time of Symptoms From Concussion
NCT02950935 16I-Prg06 Ph 3 terminated Progesterone in Threatened Abortion
NCT02841137 16CDN-Prg02 Ph 2 completed Efficacy Study of Progesterone Tablet in Post-menopausal Women
NCT02736032 12016 Ph 3 completed Cryopreserved-thawed Embryo Transfer With or Without Gonadotropin Releasing Hormone Agonist
NCT02019589 SPRY TXP13-01 Ph 3 terminated A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding for Secondary Amenorrhea
NCT01972464 results posted 1305012130 R21DA035924 Ph 2 completed Progesterone for Smoking Relapse Prevention Following Delivery
NCT02950948 16I-Prg05 Ph 3 withdrawn Progesterone in Luteal Phase Deficiency
NCT00946088 results posted SU-03312009-2078 11625 Ph 2, Ph 3 terminated Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial
NCT00646802 PROMISE PROMISE Ph 4 completed Vaginal PROgesterone as Maintenance Treatment After an epISode of prEterm Labor (PROMISE Study)
NCT01670929 PPROURM Ph 4 completed Pr-conceptional Progesterone for Unexplained Recurrent Miscarriage

Showing 50 of 62 trials

🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

MILPROSA FDA Label Details

View full patent landscape →
3 OB patents · 1 families · 74 international docs across 26 countries

MILPROSA Patents & Exclusivity

Latest Patent: Jan 2030

Patents (3 active)

US8580293 Expires Jan 21, 2030
US10548904 Expires Feb 3, 2029
US10537584 Expires Feb 3, 2029
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for MILPROSA

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2030
  • 3 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.